IDH2 and myelodysplastic syndrome: Emerging data have shown the efficacy of novel agents, including targeted IDH1 (ivosidenib) and IDH2 (enasidenib) inhibitors for cytoreduction for patients with high-risk MDS, who have been refractory with HMA inhibitors [94].